QUOTE AND NEWS
Motley Fool  Jun 6  Comment 
News that a secondary stock offering would be taking place at a discounted price caused shares of the developmental stage biotech to swoon.
Motley Fool  May 19  Comment 
Despite big gains for the market, these stocks fell. Find out why.
Motley Fool  May 19  Comment 
The need for fresh capital is a plight most drug developers face.
MarketWatch  May 18  Comment 
Halozyme Therapeutics Inc. shares fell in the extended session Thursday after the cancer-drug biotech company said it was launching a secondary offering of its stock. Halozyme shares fell 8.9% to $12.90 after hours. The company said it plans to...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki